Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones*

Abstract

Listen

Translate article

<h2>Abstract</h2> On the basis of adverse events reported to the US Food and Drug Administration, it was observed that atorvastatin-associated adverse event reports were 3.1 times more likely to list rosiglitazone or pioglitazone as a concomitant medication compared with simvastatin-associated adverse event reports.